ArticleInvestigative ophthalmology & visual science2013
The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease.
Article in Investigative ophthalmology & visual science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05784519 (Clinical Study of Mesenchymal Stem Cell Eye Drops for Treating Dry Eye Disease), which is not on this map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of Mesenchymal Stem Cell Eye Drops for Treating Dry Eye Disease
Who cites it
46 citing papers in PubMed, 76 citations in OpenAlex.
- Mechanistic Insights Into UC-MSC Therapy in a BAC-Induced Dry Eye Model: TSG-6-Dependent Inhibition of the Th17/CCL20-CCR6 Chemotactic Axis.Investigative ophthalmology & visual science · 2026Article
- Memory CD4Frontiers in immunology · 2026Review
- Associations Between Th17 Cell Markers (IL-23R, CCR6, and IL-17) and Clinical Profiles in Sjögren's Disease.Diagnostics (Basel, Switzerland) · 2025Article
- The Immunobiology of Dry Eye Disease: A Review of the Pathogenesis, Regulation and Therapeutic Implications.International journal of molecular sciences · 2025Review
- Uncovering the mysteries of human gamma delta T cells: from origins to novel therapeutics.Frontiers in immunology · 2025Review
- CD4Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Immunopeptides: immunomodulatory strategies and prospects for ocular immunity applications.Frontiers in immunology · 2024Review
- Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppressing Th17 Cell Response.Investigative ophthalmology & visual science · 2023Article
- Article
- CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases.Antibodies (Basel, Switzerland) · 2023Review
- Ocular surface immune cell diversity in dry eye disease.Indian journal of ophthalmology · 2023Review
- Effect of TRPM8 Functional Loss on Corneal Epithelial Wound Healing in Mice.Investigative ophthalmology & visual science · 2023Article
- Autoimmunity in dry eye disease - An updated review of evidence on effector and memory Th17 cells in disease pathogenicity.Autoimmunity reviews · 2021Review
- Cigarette Smoke Specifically Affects Small Airway Epithelial Cell Populations and Triggers the Expansion of Inflammatory and Squamous Differentiation Associated Basal Cells.International journal of molecular sciences · 2021Article
- Proteoglycan 4 (PRG4) expression and function in dry eye associated inflammation.Experimental eye research · 2021Article
- Toll-like receptor 2 induces pathogenicity in Th17 cells and reveals a role for IPCEF in regulating Th17 cell migration.Cell reports · 2021Article
- Differentially Expressed Gene Pathways in the Conjunctiva of Sjögren Syndrome Keratoconjunctivitis Sicca.Frontiers in immunology · 2021Article
- Recent Developments About the Pathogenesis of Dry Eye Disease: Based on Immune Inflammatory Mechanisms.Frontiers in pharmacology · 2021Review
- The role of Th17 immunity in chronic ocular surface disorders.The ocular surface · 2021Review
- Aged Mice Exhibit Severe Exacerbations of Dry Eye Disease with an Amplified Memory Th17 Cell Response.The American journal of pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTh17 cells are believed to be the primary effector cells in the pathogenesis of dry eye disease (DED). However, the mechanisms by which Th17 cells migrate from the lymphoid tissues to the ocular surface are unknown. The purpose of this study was to investigate the role of the C-C chemokine receptor 6/C-C chemokine ligand 20 (CCR6/CCL20) chemokine axis in mediating Th17 cell migration in DED.
methodsDED was induced by housing C57BL/6 mice in a low-humidity environment supplemented with scopolamine treatment. Th17 cell expression of CCR6 was evaluated using flow cytometry and ocular surface expression of CCL20 was measured using PCR and ELISA assays. CCL20 neutralizing antibody was administered subconjunctivally to DED mice and disease severity, including the frequency of conjunctival Th17 cells, was evaluated.
resultsCCR6 is preferentially expressed by Th17 cells in both normal and DED mice and DED significantly upregulates ocular surface expression of CCL20. Disruption of CCR6/CCL20 binding with CCL20 neutralizing antibody decreases T-cell migration in vitro and reduces Th17 cell infiltration of the conjunctiva when administered in vivo, significantly improving clinical signs of DED. These changes were accompanied by a decrease in ocular surface inflammatory cytokine levels and corneal CD11b+ cell frequencies. Treatment also significantly reduced the generation of Th17 cells.
conclusionsLocal neutralization of CCL20 decreases Th17 cell infiltration of the ocular surface in DED, leading to improvement in clinical signs of disease. This suggests that CCR6/CCL20 interactions direct Th17 cell migration in DED and that disruption of this axis may be a novel therapeutic approach to this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.